BDTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Black Diamond Therapeutics Inc (BDTX) is not a strong buy for a beginner, long-term investor at this time. While the technical indicators show some positive momentum, the stock's overbought RSI, lack of significant trading trends, weak financial performance, and absence of recent news or catalysts suggest limited upside potential in the near term. A hold position is recommended until clearer growth signals or catalysts emerge.
The MACD is positive and expanding (0.0715), indicating bullish momentum. However, the RSI is at 83.863, signaling the stock is overbought. Moving averages are converging, showing indecision. Key resistance levels are at 2.878 and 3.039, with support at 2.359 and 2.198.
Analyst Wedbush raised the price target to $14, citing optimism about silevertinib's clinical development. The MACD indicates positive momentum.
The RSI indicates the stock is overbought. Financial performance is weak, with negative net income (-$15.12M) and declining EPS (-7.14% YoY). No recent news or significant insider/hedge fund trading trends.
In Q4 2025, revenue remained at $0. Net income dropped to -$15.12M (-5.44% YoY), and EPS declined to -0.26 (-7.14% YoY). Gross margin remained at 100%, but the company is not generating revenue.
Wedbush maintains an Outperform rating and raised the price target to $14 from $13, citing optimism about silevertinib's clinical development and upcoming data readouts.
